Anti-CD74 antibody (milatuzumab) was developed for medical use, particularly in the treatment of hematologic cancers such as non-Hodgkin’s lymphoma and multiple myeloma (plasma cell cancer). CD74 protein is highly expressed on the surface of abnormal immune cells in these diseases, making it a suitable target for specific therapy.

Milatuzumab works by binding to CD74 protein, which inhibits signaling necessary for cancer cell survival and proliferation. Additionally, it facilitates the delivery of toxins into cancer cells when used in conjunction with chemotherapy or radioactive substances in the form of antibody-drug conjugates.

Clinical studies have shown that milatuzumab has potential to reduce tumor size and control disease progression, especially in patients refractory to other treatments. It is currently under investigation to evaluate efficacy and safety in additional diseases, including combination with other immunotherapies.